Clinical Trial Update: Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients. [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the efficacy and safety of an immunomodulator as adjunct therapy in patients with newly diagnosed pulmonary tuberculosis (Category I)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Tuberculosis

Drugs mentioned

• Immunomodulator (immunomodulator)

Snippet

Sponsor: Ministry of Science and Technology, India | Conditions: Tuberculosis | Phase 3 | Status: COMPLETED